IDEXX Laboratories, Inc.

IDXX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2009 FY2008
Operating Activities
Net Income $122.2M $116.2M
Depreciation & Amortization $49.8M $48.0M
Depreciation — —
Amortization $9.4M —
Stock-Based Compensation $11.6M $10.5M
Net Cash from Operating Activities $175.0M $143.3M
Investing Activities
Capital Expenditures $50.7M $90.0M
Business Acquisitions $7.9M $3.9M
Net Cash from Investing Activities $-53.6M $-91.6M
Financing Activities
Dividends Paid — —
Stock Repurchases $83.1M $132.3M
Net Cash from Financing Activities $-95.3M $-30.8M
Net Change in Cash $27.9M $18.5M
Free Cash Flow $124.3M $53.3M
← Newer Page 3 of 3 Older →